+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Scynexis Inc - logo

SCYNEXIS is a drug development company that develops and commercializes anti-infectives to address unmet therapeutic needs. Its lead product candidate, SCY-078, is a novel and structurally distinct triterpenoid glucan synthase inhibitor. SCY-078 is in Phase 2 clinical development as an oral and intravenous drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. Founded in 1999, the company is headquartered in Jersey City, New Jersey.

Outsourcing in Drug Discovery, 9th Edition - Product Thumbnail Image

Outsourcing in Drug Discovery, 9th Edition

  • Report
  • June 2020
  • 294 Pages
  • Global
From
Vulvovaginal Candidiasis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update - Product Thumbnail Image

Vulvovaginal Candidiasis Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type, and Top Countries, 2022 Update

  • Report
  • March 2022
  • 170 Pages
  • Global
From
Fungal Infections - Global Clinical Trials Review, H2, 2021 - Product Thumbnail Image

Fungal Infections - Global Clinical Trials Review, H2, 2021

  • Clinical Trials
  • December 2021
  • 974 Pages
  • Global
From
SCYNEXIS Inc (SCYX:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry - Product Thumbnail Image

SCYNEXIS Inc (SCYX:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry

  • Company Profile
  • May 2023
  • 89 Pages
From
Comprehensive Report on SCYNEXIS Inc, including SWOT, PESTLE and Business Model Canvas - Product Thumbnail Image

Comprehensive Report on SCYNEXIS Inc, including SWOT, PESTLE and Business Model Canvas

  • SWOT Analysis
  • August 2023
  • 90 Pages
From
Loading Indicator